Observational Study
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 907-918
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.907
Table 1 Basic information of duodenal neuroendocrine tumour patients, n (%)
Clinical features
Duodenal neuroendocrine tumours (n = 29)
Gender
Males34.5 (10/29)
Females65.5 (19/29)
Tumour site
Ampullary region24.1 (7/29)
Nonampullary region75.9 (22/29)
Age at diagnosis
Median age (yr)55.7 ± 10.3
30-397.0 (2/29)
40-4924.1 (7/29)
50-5934.5 (10/29)
60-6924.1 (7/29)
≥ 7010.3 (3/29)
Symptoms
Abdominal pain51.7 (15/29)
Abdominal distension17.2 (5/29)
Acid reflux17.2 (5/29)
Nausea13.8 (4/29)
Vomiting3.4 (1/29)
Black stools7.0 (2/29)
Poor appetite 7.0 (2/29)
No symptoms20.7 (6/29)
Tumour size2.6 ± 1.6 cm
≤ 1 cm13.8 (4/29)
1-2 cm20.7 (6/29)
≥ 2 cm65.5 (19/29)
Histological classification and grading
NET-G148.3 (14/29)
NET-G244.8 (13/29)
NET-G33.4 (1/29)
NEC3.4 (1/29)
Tumour staging
I13.8 (4/29)
II55.2 (16/29)
III13.8 (4/29)
IV17.2 (5/29)
Tumour type
Nonfunction96.6 (28/29)
Function(gastrinoma)3.4 (1/29)
Surgery
Yes86.2 (25/29)
No13.8 (4/29)
Postoperative chemotherapy
Yes20.7 (6/29)
No79.3 (23/29)
Survival status
Death41.4 (12/29)
Survival58.6 (17/29)
Table 2 Comparison clinical features of duodenal neuroendocrine tumour patients in ampullary region and nonampullary region
Clinical features
Ampullary region (n = 7)
Nonampullary region (n = 22)
Statistical value
P value
Males/females (n/n)1/69/13Fisher exact test0.367
Age at diagnosis (yr)59.256 ± 11.36854.546 ± 9.99t = 1.0590.299
Tumour size (cm)2.543 ± 1.3162.696 ± 1.648t = -0.2230.826
Survival time (month)10 (8, 30)71.5 (35, 123)Z = -3.2380.000
Histological classification and grading, n (%)Fisher exact probability method = 4.0980.241
    NET-G12 (28.6)12 (54.5)
    NET-G24 (57.1)9 (41)
    NET-G31 (14.3)0 (0)
    NEC0 (0)1 (4.5)
Tumour staging, n (%)Fisher exact probability method = 6.9960.036
    I2 (28.6)2 (9.1)
    II11 (14.3)15 (68.2)
    III2 (28.6)2 (9.1)
    IV2 (28.6)3 (13.6)
With/without functional tumours (n/n)1/60/22Fisher exact test0.241
With/without surgery (n/n)5/220/2Fisher exact test0.238
With/without chemotherapy (n/n)1/65/17Fisher exact test0.545
Death/survival (n/n)6/16/16Fisher exact test0.011
Table 3 Univariate and multivariate analysis of overall survival of duodenal neuroendocrine tumour patients
Factor
        Univariate analysis
        Multivariate analysis
        HR (95%CI)P value        HR (95%CI)P value
Tumour staging8.000 (5.060-10.940)0.003 -
Surgery (with/without)8.000 (6.303-9.697)0.000 0.029 (0.004-0.199)0.000
Tumour site (ampullary/nonampullary region)10.000 (8.829-11.171)0.000 12.609 (2.889-55.037)0.001
Table 4 Basic information of nonampullary duodenal neuroendocrine tumours patients, n (%)
Clinical features
Tumour size (diameter)
< 2 cm (n = 8)
≥ 2 cm (n = 14)
Gender
    Males12.5 (1/8)57.1 (8/14)
    Females87.5 (7/8)42.9 (6/14)
Age at diagnosis
Median age (yr)
    < 6575 (6/8)85.7 (12/14)
    ≥ 6525 (2/8)14.3 (2/14)
Symptoms
    Abdominal pain12.5 (1/8)57.1 (8/14)
    Abdominal distension12.5 (1/8)85.7 (12/14)
    Acid reflux25 (2/8)0 (0/14)
    Nausea0 (0/8)14.3 (2/14)
    Vomiting0 (0/8)7.1 (1/14)
    Black stools0 (0/8)14.3 (2/14)
    Poor appetite 0 (0/8)14.3 (2/14)
    No symptoms50 (4/8)14.3 (2/14)
Histological classification and grading
    NET-G162.5 (5/8)50 (7/14)
    NET-G225 (2/8)50 (7/14)
    NET-G30 (0/8)0 (0/14)
    NEC12.5 (1/8)0 (0/14)
Tumour staging
    I25 (2/8)0 (0/14)
    II75 (6/8)64.3 (9/14)
    III0 (0/8)14.3 (2/14)
    IV0 (0/8)21.4 (3/14)
Surgery
    Yes100 (8/8)85.7 (12/14)
    No0 (0/8)14.3 (2/14)
Postoperative chemotherapy
    Yes12.5 (1/8)28.6 (4/14)
    No87.5 (7/8)71.4 (10/14)
Survival status
    Death0 (0/8)42.9 (6/14)
    Survival100 (8/8)57.1 (8/14)
Table 5 Clinical characteristics comparison of nonampullary duodenal neuroendocrine tumour patients
Clinical features
Tumour size (diameter)
Statistical value
P value
< 2 cm (n = 8)
≥ 2 cm (n = 14)
Males/females (n/n)1/78/6Fisher exact test0.052
Age at diagnosis (yr)56.50 ± 12.0053.43 ± 8.97t = 0.6840.502
Survival time (month)191.25 ± 175.4742.93 ± 30.49t = 7.2430.048
Histological classification and grading, n (%)Fisher exact probability method = 5.0900.120
NET-G157
NET-G227
NET-G300
NEC10
Tumour staging, n (%)Fisher exact probability method = 2.4590.363
I20
II69
III02
IV03
With/without surgery (n/n)8/812/2Fisher exact test0.515
With/without chemotherapy (n/n)1/74/10Fisher exact test0.394
Death/survival (n/n)0/88/14Fisher exact test0.051